DPP-IV inhibitors: A review of sitagliptin, vildagliptin, alogliptin, and saxagliptin

Formulary

Volumn 43, Issue 4, 2008, Pages 122-134

  Miller, Shannon A ^a,b   St Onge, Erin L ^c   Taylor, James R ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b FLORIDA HOSPITAL   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIGOXIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; BODY WEIGHT; CELL FUNCTION; CLINICAL TRIAL; COUGHING; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; LONG TERM CARE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PROTEIN DEGRADATION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STOMACH EMPTYING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE; WEIGHT GAIN;

EID: 42949178414     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Centers for Disease Control and Prevention website. Diabetes: Sounding the alert on a debilitating disease. http://www.cdc.gov/features/diabetesalert/. Accessed March 21, 2008.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
3. Nathan DM, Busc JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes [erratum in Diabetes Care. 2006;49:2816-2818]. Diabetes Care. 2006;29:1963-1972.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [erratum in N Engl J Med. 2007;357:100]. N Engl J Med. 2007;356:2457-2471.
5. McIntosh CH, Demuth HU, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? Regul Pept. 2005;128:159-165.
6. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004;47:4135-4141.
7. Lauster CD, McKaveney TP, Muench SV. Vildagliptin: A novel oral therapy for type 2 diabetes mellitus. Am J Health Syst Pharm. 2007;64:1265-1273.
8. Creutzfeldt W. The [pre-] history of the incretin concept. Regul Pept. 2005;128:87-91.
9. Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6- dihydro[1,2, 4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan- 2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141-151.
10. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609-613.
11. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract. 2007;61:171-180.
12. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006;49:2564-2571.
13. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632-2637.
14. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:186-193.
15. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979-1987.
16. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638-2643.
17. Nauck M, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007;9:194-205.
18. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733-745.
19. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556-1568.
20. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:2078-2084.
21. Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes Obes Metab. 20057:692-698.
22. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res. 2006;38:423-428.
23. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218-223.
24. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007;76:132-138.
25. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes : A 24-week, double-blind, randomized, trial [erratum in Diabetes Care. 2007;30:1330]. Diabetes Care, 2007;30:217-223.
26. Ahren B, Gomis R, Standi E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874-2880.
27. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890-895.
28. Rosenstock J, Baron MA, Lebeaut A. The use of vildagliptin for treatment of patients with type 2 diabetes [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13,2006; Washington, DC. Abstract 6-LBCS.
29. Fonseca V, Dejager S, Albrecht D, Shirt L, Schweizer A. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM) [abstract]. Presented at: American Diabetes Association 66th Annual Scientific Sessions; June 9-13, 2006; Washington, DC. Abstract 467-P.
30. Christopher R, Covington P, Davenport M, et al. Pharmacokinetics, pharmacodynamics, and tolerability of multiple doses of alogliptin benzoate (SYR-322), a dipeptidyl peptidase-IV inhibitor, in patients with type 2 diabetes [abstract]. Presented at: American Diabetes Association 67th Annual Scientific Sessions; June 22-26, 2007; Chicago, IL. Abstract 0499-P.
31. Defronzo RA, Hissa M, Blauwet MB, Chen RS. Saxagliptin added to metformin improves glycemia control in patients with type 2 diabetes [abstract]. Presented at: American Diabetes Association 67th Annual Scientific Sessions; June 22-26, 2007; Chicago, IL. Abstract 02850OR.
32. Januvia [package insert]. Whitehouse Station, NJ: Merck & Co; 2007.
33. Red Book. 2007 edition. Montvale, NJ: Thompson PDR; 2007.
34. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9-24.